AstraZeneca has revised the efficacy rate for its US Covid-19 vaccine trial down to 76 per cent as the pharmaceutical group sought to address concerns that it had published incomplete interim data earlier this week.
阿斯利康(AstraZeneca)将其美国新型冠状病毒肺炎（COVID-19，即2019冠状病毒病）疫苗临床试验的有效率向下修正为76%。该制药集团寻求化解本周早些时候出现的、认为其发表了不完整的中期数据的担忧。
您已阅读9%（322字），剩余91%（3094字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。